EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling... January 19, 2026 FDA Approvals Bring New Options for Older Patients with AML December 27, 2018 FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... August 18, 2023 Caregivers Empower the Next Generation of Cancer Care August 3, 2023 Load more HOT NEWS Withdrawal of the Application to Change the EMA Marketing Authorisation for... EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... Prising open the trap: Getting to grips with targeted cancer drug...
